Expressive

rs114204800 (ADAM29-TSEN2P1): AMD Complement Research

Key takeaways

  • Elevated blood levels of FHR-1 and FHR-2 showed the strongest statistical links to advanced AMD in a case-control study
  • Factor H (FH) protein levels did not differ between AMD patients and controls, while five related proteins did
  • Mendelian randomization - a method for testing causation - supported FHR-1, FHR-2, FHR-4, and FHR-5 as true drivers of AMD risk
  • Evidence directly tying rs114204800 to these findings is preliminary based on the available study text

Key takeaways

  • Elevated blood levels of FHR-1 and FHR-2 showed the strongest statistical links to advanced AMD in a case-control study
  • Factor H (FH) protein levels did not differ between AMD patients and controls, while five related proteins did
  • Mendelian randomization - a method for testing causation - supported FHR-1, FHR-2, FHR-4, and FHR-5 as true drivers of AMD risk
  • Evidence directly tying rs114204800 to these findings is preliminary based on the available study text

What the research says One study examined how genetic variation at the complement factor H (CFH) locus - a chromosomal gene cluster at 1q31.3 encoding complement regulators FH, factor-H-like protein 1 (FHL-1), and five factor-H-related proteins (FHR-1 through FHR-5) - influences circulating protein levels in people with and without advanced age-related macular degeneration (AMD), a leading cause of vision loss projected to affect roughly 290 million people by 2040. Using a targeted mass-spectrometry assay on samples from 352 advanced AMD cases and 252 controls, researchers found significantly elevated concentrations of FHL-1 and all five FHR proteins in AMD cases, while FH itself showed no significant difference (p = 0.94); genome-wide association analyses identified signals at the locus for all five FHR proteins, and Mendelian randomization - a statistical method for testing causality - supported FHR-1, FHR-2, FHR-4, and FHR-5 as causal contributors to AMD susceptibility.

Reported associations

  • Age-related macular degeneration (AMD): Elevated FHR-1 (p = 2.4 × 10^-¹^0), FHR-2 (p = 6.0 × 10^-¹^0), FHR-3 (p = 1.5 × 10^-5), FHR-4 (p = 1.3 × 10^-³), FHR-5 (p = 1.9 × 10^-4), and FHL-1 (p = 4.9 × 10^-4) blood concentrations were each observed in 352 advanced AMD patients versus 252 controls; Mendelian randomization supported FHR-1, FHR-2, FHR-4, and FHR-5 as causal contributors to this trait.

Evidence quality The study enrolled 352 advanced AMD cases and 252 controls and employed a validated LC-SRM-MS (liquid-chromatography-selected reaction-monitoring mass spectrometry) assay capable of simultaneously measuring all seven complement regulators at the CFH locus - a methodological strength that reduces the cross-reactivity typical of antibody-based assays. Genome-wide association analyses and Mendelian randomization provide strong statistical grounding for the FHR-AMD associations. However, the available study text does not identify rs114204800 by name among detected genetic signals, and no replication data specific to this variant appear in the provided excerpt; evidence linking this variant directly to AMD should therefore be considered preliminary.

Lifestyle considerations No lifestyle considerations on file for this variant.

Frequently asked questions

What is rs114204800?

rs114204800 is a genetic variant located near the ADAM29 gene and the TSEN2P1 pseudogene. Research associated with this variant involves complement protein regulation and age-related macular degeneration genetics.

Is rs114204800 linked to age-related macular degeneration?

The study associated with this variant found that elevated FHR complement protein levels are causally tied to AMD risk. The available study text does not explicitly name rs114204800 among the detected variants, so this connection is considered preliminary.

What are FHR proteins and why do they matter for AMD?

Factor-H-related (FHR) proteins are blood-circulating complement regulators encoded near the CFH gene. Unlike factor H, which helps suppress inflammation, FHR proteins can amplify complement activation; the study found that elevated FHR-1, FHR-2, FHR-4, and FHR-5 levels appear to causally increase AMD risk.

Why did factor H show no difference in AMD patients?

Blood levels of factor H (FH) itself were not significantly different between AMD patients and controls (p = 0.94) in the study, suggesting that FH is not the primary driver of AMD risk at this locus - its related proteins FHR-1 through FHR-5 appear to be the active contributors.